Tag Archives: Anthony Fauci

Fauci messing up monkeypox just like COVID, Ebola and AIDS

Once, I believed that the world is run by experts who know what to do. I believed that the best answer to a crisis is to listen to the experts and do what they say because they know best and can be trusted to have our interests at heart.

Yeah, I was an idiot. In my defense, I was young. Now I know better.

The list of expert failures is a long one. The Vietnam War, which predated my youthful enthusiasm for experts, was launched by what David Halberstam mockingly called “the best and the brightest” in a book by the same name. 

They were well-educated, or at least well-credentialed, spoke with skill and enjoyed the regard of other ruling-class people. And they produced a debacle of the first order.

Since then, we have seen numerous instances of expert incompetence — just look at the management of the economy right now — but one of the most striking is the ongoing, generational ineptitude of the Centers for Disease Control and Prevention and the rest of the public-health establishment in dealing with disease outbreaks.

Protester holds a sign with Joe Biden saying, “where are the shots?” during the demonstration at Foley Square to demand more monkeypox vaccinations be made available to the public.
Karla Coté/SOPA Images/Shutterstock

The latest example is the government’s handling of monkeypox, which the Biden administration just declared a public-health emergency. As The New York Times recently reported, the US government had 20 million doses of monkeypox vaccine less than a decade ago. (It’s actually a smallpox vaccine called Jynneos, also effective against monkeypox.) But when we needed it, the so-called National Strategic Stockpile had only 2,400 doses on hand, enough to vaccinate just 1,200 people.

How did this happen? Bureaucratic incompetence and Food and Drug Administration foot-dragging. Bureaucrats allowed the vaccine to expire without being replaced because they wanted to develop a freeze-dried version with a longer shelf life. But FDA delays in approval meant that the new vaccine didn’t appear even as the old vaccine expired. The end result was that when a vaccine was needed, nothing was available.

“I want people to know how poorly this went given the amount of money and resources put into it,” declares former CDC official Dr. Ali S. Khan.

Well, yes. Worse yet, this vaccine — which was also intended to deal with a bioterror-inspired smallpox outbreak — was stored outside the United States in the facilities of the Danish manufacturer, which caused logistical issues of its own.

“The CDC was supposed to have spent the last 2+ decades preparing for the specific scenario of ‘What if someone resurrects Smallpox and releases it as a bioweapon’. Now, when faced with a virus that is literally ‘Story Mode Smallpox’ they fail,” researcher Nicholas Weaver observes. Monkeypox “is not hyper-virulent,” he notes, and vaccines, treatments and techniques, such as contact tracing, designed for smallpox work just as well. Yet the CDC has “failed, completely and utterly, to prevent this growing.”

A pharmacist removes a tray of vials of the Jynneos vaccine for monkeypox at a vaccine hub in San Francisco.
Lea Suzuki/San Francisco Chronicle/AP

Well, it’s not the first time. The health establishment’s incompetence with regard to COVID is infamous. First, National Institute of Allergy and Infectious Diseases chief Anthony Fauci downplayed the threat, only to turn on a dime and pronounce it deadly. The CDC developed a defective test for COVID, then for months blocked other institutions from distributing competing tests that worked. (It’s doing the same thing with monkeypox tests.) Fauci also executed a 180-degree turn on masking and promoted lockdowns, which the World Health Organization concluded do more harm than good.

But the CDC’s ineptitude goes farther back than that. During the 2014 Ebola outbreak, the CDC also failed, admitting its performance was “rocky” as it saw itself outperformed in many ways by health officials in countries like Nigeria. That debacle, five years before COVID’s emergence, should have been a wakeup call — but the agency slept on.

And of course, the CDC’s performance during the 1980s AIDS outbreak, when Fauci first became famous, was abysmal. Fauci in particular pushed the false notion that run-of-the-mill heterosexuals were at risk for AIDS in the same fashion as gays and intravenous-drug users, which wasn’t true. It both spread unnecessary fear and diluted efforts to aid at-risk populations. There’s not much of a learning curve here.

We’d like to live in a world where we can trust the experts, both to know what to do and to promote policies that will help us. But we don’t live in that world. Maybe we need better experts. The ones we have don’t seem especially expert at all.

Fauci participates in a panel at the National AIDS Update Conference on October 12, 1989.
Deanne Fitzmaurice/The San Francisco Chronicle/Hearst Newspapers via Getty Images

Or maybe we need to think for ourselves.

Glenn Harlan Reynolds is a professor of law at the University of Tennessee and founder of the InstaPundit.com blog.



Read original article here

Scientists Are Testing a Universal Flu Vaccine In People

Image: Shutterstock (Shutterstock)

The race to one of medicine’s elusive goals—a universal flu vaccine—is heating up. On Tuesday, the National Institutes of Health announced the phase I clinical trial of one such potential candidate, which will involve up to 100 adult volunteers. In early experiments, the vaccine appeared to protect animals exposed to fatal doses of multiple influenza strains.

The vaccine candidate is known as BPL-1357 and is being developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). It contains four strains of avian influenza viruses that aren’t thought to be highly pathogenic, which are then further weakened and made unable to replicate.

In trials with both mice and ferrets, BPL-1357 suggested the tantalizing promise of a universal buffer against the flu. Mice given BPL-1357 were able to survive lethal doses of six different flu strains, for instance, which included two subtypes that weren’t directly covered by the vaccine.

By contrast, our current seasonal flu vaccines can cover multiple strains, but have to be updated every year. They also tend to only provide modest protection against the flu, in part because the strains circulating in the world continue to evolve and don’t quite look like the strains selected to be in the vaccine months earlier. Another challenge is that they often don’t induce an immune response in the mucus-filled regions of our nose, throat and lungs, which is an important aspect of fighting off respiratory viruses like the flu.

Like the seasonal flu vaccine, BPL-1357 can be delivered as a nasal spray or intramuscularly with a shot. The vaccine’s trial will recruit volunteers between the ages of 18 to 55 and randomly sort them into three groups. One group will first receive a dose of BPL-1357 as a shot, then a saline placebo nasal spray; the other will receive a placebo shot, then the vaccine as a nasal spray; and the last will receive both a placebo shot and nasal spray. The groups will then be monitored and regularly undergo blood and nasal swab tests for about seven months.

Phase I trials are meant primarily to test the safety of a new drug or vaccine. But the samples collected from volunteers will allow researchers to get an early sense of whether BPL-1357 can induce a broad and durable immune response to the influenza virus in people. It may also show that one method of delivery is likely to be better than the other.

Vaccines given intranasally are typically better at inducing these kinds of mucosal immune responses. And if BPL-1357 can deliver on its potential, then it may not only protect us from the seasonal flu but future emerging strains passed down from birds and other animals that could threaten to become the next pandemic. That said, other universal flu vaccine candidates have crashed and burned over the years, so it will take time to tell whether BPL-1357 is the real deal. The trial is expected to be completed by early next year.

“Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses as well as those with pandemic potential would be invaluable public health tools,” said NIAID Director Anthony Fauci in a statement. “The scientific community is making progress on this pressing global health priority. The BPL-1357 candidate influenza vaccine being tested in this clinical trial performed very well in pre-clinical studies and we look forward to learning how it performs in people.”

Read original article here

Dr. Fauci talks COVID after Pfizer’s Paxlovid treatment

The quadruple-vaccinated Dr. Anthony Fauci said he is experiencing a “much worse” COVID rebound after being treated with Pfizer’s antiviral medication Paxlovid.

The 81-year-old chief medical adviser to the White House revealed his health struggles while speaking remotely at the Foreign Policy Global Health Forum on Tuesday.

The nation’s leading infectious disease expert tested positive for COVID-19 on June 15 and was initially experiencing mild symptoms, according to a statement released at the time by the National Institutes of Health.

When his condition took a turn for the worse, he began a five-day course of Paxlovid, which was granted an emergency use authorization by the Food and Drug administration in December 2021 to treat high-risk COVID patients in an effort to prevent hospitalizations and deaths.

Paxlovid is Pfizer’s antiviral drug that received emergency use authorization from the FDA in December 2021 to treat high-risk COVID patients.
REUTERS

Fauci said Tuesday that after he recovered from his initial bout with the coronavirus, he tested negative for three days, but then tested positive again on the fourth day, reported the San Francisco Chronicle.

“And then over the next day or so, I started to feel really poorly, much worse than in the first go-around,” Fauci said. “So I went back on Paxlovid and right now I am on my fourth day of a five-day course.”

The scientist added that he is feeling better but “not completely without symptoms.”

In April, the Biden administration announced it was expanding the availability of Paxlovid, touting it as “one of the most effective treatments in our nation’s medicine cabinet.”

A month later, the US Centers for Disease Control and Prevention issued a warning regarding a COVID-19 rebound after Paxlovid treatment. 

Dr. Fauci said he had completed a five-day course of Paxlovid, after which he tested positive again for COVID and was feeling much worse.
REUTERS

The agency said some patients who were prescribed a course of Paxlovid experienced a recurrence of COVID symptoms or tested positive for the disease between two and eight days after the initial recovery. 

The CDC suggested that “a brief return of symptoms may be part of the natural history of (COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status.”

The statement added that there have been no reports of severe illness associated with rebound cases.

According to a new study by the University of California San Diego School of Medicine, COVID-19 rebound after Paxlovid treatment was likely caused by insufficient exposure to the drug because not enough of it was getting to infected cells to stop all viral replication.

The authors of the study suggested this may be due to Paxlovid being metabolized more quickly in some patients, or that the drug needs to be delivered over a longer treatment duration.

Read original article here

Kid Rock to Tucker Carlson: ‘F— Fauci’

Musician Kid Rock slammed Dr. Anthony FauciAnthony FauciSome states pull back on daily COVID reporting Hvistendahl: Reports that U.S.-funded lab leaked COVID-19 are ‘dangerous’ Fauci says US unlikely to see surge from new COVID-19 variant MORE in a Fox News interview, telling host Tucker CarlsonTucker CarlsonFree flow of information crucial in troubled world Five things to watch for during Zelensky’s address to Congress Panel on ‘The View’ calls for DOJ to probe Tucker Carlson over Putin rhetoric MORE, “F— Fauci,” when asked about the leading infectious disease physician.

Carlson responded to his comment, saying “you speak for many when you say that.”

Kid Rock, whose real name is Robert James Ritchie, added that he believed all the “bullshit” at the beginning of the pandemic and was “spraying off UPS packages” and doorknobs.

“A couple moths of that shit and I’m like, what? So this is pretty much knocking out overweight, unhealthy people?” he added. “I’m like, I’m good.”

The full interview will air on Fox News Monday night at 8 p.m. ET.

The conservative rocker has long been critical of Fauci and COVID-19 mitigation policies. He previously released an expletive-filled anti-Biden anthem where he repeats the phrase, “Let’s go, Brandon.”

“Wear your mask, take your pills. Now a whole generation is mentally ill,” says one line in the song.

Fauci said last year that conservative attacks against him were “attacks on science.”

“It’s very dangerous,” he said on MSNBC, “because a lot of what you’re seeing as attacks on me quite frankly are attacks on science, because all of the things that I have spoken about consistently from the very beginning, have been fundamentally based on science.”

In another teaser for Monday’s interview, Kid Rock was asked “Why haven’t you been canceled?” 

“I am uncancelable,” Kid Rock said while wearing a “We The People” hat.

“I’m not in bed with any big corporate things. At the end of the day, there’s nobody I’m beholden to — no record companies, no corporate interests, no nothing. You can’t cancel me,” he said. “I love it when they try.”

The 51-year-old musician is vocal supporter of former President TrumpDonald TrumpNow is the time to rebuild America’s refugee resettlement program Is a post-Trump media world beginning to take shape? Major government surveillance revelations fail to make a big splash MORE and praised him in another preview of the interview released on Monday.

“See now, if you watch a Joe BidenJoe BidenBiden to visit Poland during Europe trip Former DC judge, Penn law professor to introduce Ketanji Brown Jackson at hearing US concludes violence against Myanmar’s Rohingya was genocide: report MORE interview, and you watch a Trump interview, there’s no comparison. And Trump speaks off the cuff. I understand what it’s like, sometimes you get it wrong. But I would way rather hear somebody come from here [the heart] and get it wrong once in a while,” he added.

Kid Rock shared an anecdote of standing next to Trump in the White House, watching him read one line from prepared notes and then ad-libbing after that. “That’s why I liked him from the beginning,” Kid Rock said. 

His interview comes on the same day of the digital release of his new album, “Bad Reputation.” 



Read original article here

Pelosi says White House should request $45B in new COVID aid

Speaker Nancy PelosiNancy Pelosi Irish PM tests positive for COVID-19 during visit to DC Five takeaways from Zelensky’s virtual address to Congress House relearns history of legislative surprise rule MORE (D-Calif.) on Thursday said she’s advised the Biden administration to seek tens of billions of dollars more in emergency COVID-19 relief, suggesting it will take more than $40 billion to meet the testing, vaccine and therapeutic needs of the U.S. and the larger global community.

President BidenJoe Biden Irish PM tests positive for COVID-19 during visit to DC CNN anchor breaks down talking to Ukrainian father whose family was killed Graham introduces resolution urging Biden to help send jets to Ukraine MORE had initially asked Congress for $22.5 billion in new funding to fight the ongoing pandemic — a figure that was whittled down to $15.6 billion in the face of Republican opposition on Capitol Hill.

Pelosi on Thursday said that even the larger $22.5 billion figure was too small, arguing it would provide relief only through the early part of the summer before Congress would need to approve more.

“I think they should be double what they asked for, because even when they were asking for like 20-some [billion dollars] it was only going to get us to June,” Pelosi told reporters in the Capitol.

The comments arrived shortly after Pelosi and other Democratic leaders huddled in the Capitol with the Biden administration’s top health officials, including Health and Human Services Secretary Xavier BecerraXavier BecerraHouse Democrats press Becerra on access to abortion medication Biden signs reauthorization of the Violence Against Women Act The Hill’s 12:30 Report – Zelensky shows emotional footage in plea to lawmakers MORE and Anthony FauciAnthony FauciOvernight Health Care — Scalise wants Fauci to testify Scalise calls for Fauci to testify at upcoming hearing Senate panel advances pandemic preparedness bill on bipartisan vote MORE, the nation’s top infectious disease specialist.

In seeking $22.5 billion for COVID relief earlier this month, the administration had said it would cover the “immediate needs” of the pandemic response “over the next few months.”

The request proposed that a large bulk of the funding — $18.25 billion — would go to Becerra’s agency, while the remaining $4.25 billion would provide help abroad through the State Department and U.S. Agency for International Development.

Republicans balked at the figure, saying it was both too high and needed to be paid for by spending cuts elsewhere in the budget. Bipartisan negotiators came to agreement on the $15.6 billion figure, which was fully offset.

The proposal hit a brick wall in the House last week, however, when rank-and-file Democrats revolted over one of the pay-for provisions, which would have clawed back more than $7 billion from state COVID-19 funds allocated last March as part of Biden’s American Rescue Plan.

The opposition forced Pelosi to yank the COVID-19 funding from the larger spending package, and return to the drawing board in search of another source of offset funding.

Pelosi, who was reportedly furious with the Democratic critics, said Thursday that whatever bill emerges will be fully paid for — whatever the ultimate cost.

“What I’ve said to the administration is … you must ask for more. Because we need more, and you can’t expect money, this [bill], to turn around just like that because the legislative process takes time,” she said. “We want it to be bipartisan; we need it to be paid for. And so let’s just go for a bigger chunk.”

The Speaker did not provide a timeline for House action on the bill, but suggested she wanted to move quickly.

“I think we have to get on with it,” she said.

Pelosi’s press conference came just hours after she dined with Irish Prime Minister Michael Martin on Wednesday evening. Shortly afterwards, Martin tested positive for COVID-19 — a development that’s sparked some concern in the Capitol since Pelosi is hosting Biden on Thursday afternoon for the annual luncheon honoring St. Patrick’s Day.

Pelosi dismissed those concerns, saying she’s tested “almost every day.”



Read original article here

New Moderna mRNA Vaccines for HIV Start Clinical Trial

Vials of Moderna’s covid-19 vaccine, formally known as Spikevax.
Photo: Thomas Lohnes (Getty Images)

The next generation of potential vaccines for HIV are set to be tested in humans. This week, the U.S. National Institutes of Health launched an early clinical trial that will track the safety of three experimental HIV vaccines, all being developed by Moderna and based on its mRNA technology, the same platform used for its FDA-approved covid-19 vaccine.

mRNA is a vital part of how our cells function. It contains the genetic instructions needed for cells to produce proteins. Normally, this mRNA is carried over from the cell’s DNA, but mRNA vaccines deliver their own packet of instructions to cells. In the case of covid-19, the vaccines tell our cells to produce the spike protein of the SARS-CoV-2 coronavirus, a key part of the virus that allows it to infect cells. The spike protein alone can’t cause an infection, but it’s enough to trigger the immune system into action and train our body to better fend off the virus if it ever shows up.

The same principle underlies the three HIV vaccine candidates now being tested by the NIH. They’re all designed to have the body’s cells produce the spike protein of HIV, though they’re encoding slightly different but closely related proteins. Moderna is developing the shots in collaboration with scientists at the Scripps Consortium for HIV/AIDS Vaccine Development at the Scripps Research Institute and the Bill & Melinda Gates Foundation-funded IAVI Neutralizing Antibody Center at Scripps. (This is the only latest foray into HIV vaccine research by Moderna; last summer, it launched a Phase I trial of a different candidate.)

“Finding an HIV vaccine has proven to be a daunting scientific challenge,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, in a statement on Monday. “With the success of safe and highly effective COVID-19 vaccines, we have an exciting opportunity to learn whether mRNA technology can achieve similar results against HIV infection.”

The trial will involve up to 108 healthy adults between ages of 18 and 55 at 11 research sites across the U.S. It will be divided in two groups, with the first group being evaluated two weeks after the first shot to ensure the safety of the vaccines, before the second group is vaccinated with a higher dose version. Should everything go as planned, the volunteers will receive three shots, with the second and third doses taken two months and six months after the first. The trial is expected to conclude by July 2023.

Phase I trials are primarily intended to test the safety of a new drug or vaccine. But the trial will also collect data on people’s immune responses, which should provide the first clues as to whether this approach really can work as hoped.

Read original article here

FDA considering second COVID-19 booster in coming months

Food and Drug Administration (FDA) officials are “very carefully” considering second booster doses of the mRNA COVID-19 vaccines, according to The Wall Street Journal.

FDA spokesperson Alison Hunt confirmed to CNN that the FDA “is indeed continually looking at the emerging data on the pandemic and variants in the United States and overseas in order to evaluate the potential utility and composition of booster doses.”

Hunt also said that there is still much uncertainty, but the FDA is evaluating whether another booster dose will be needed when the country moves into the fall of 2022, which would coincide with the typical administration of annual flu shots, CNN noted.

“As more data become available about the safety and effectiveness of COVID-19 vaccines, including the use of a booster dose, we will continue to evaluate the rapidly changing science and keep the public informed,” Hunt wrote to CNN. “Any determination that additional booster doses are needed will be based on data available to the agency.”

If the FDA approves another booster dose, it would then face approval by the Centers for Disease Control and Prevention (CDC). 

Anthony FauciAnthony FauciFDA considering second COVID-19 booster in coming months GOP senator faces challenge on Trump credentials Britt in new ad tells ‘boys in Washington’ to ‘man up’ MORE, the head of the National Institute of Allergy and Infectious Diseases (NIAID), said the “potential future requirement” for an additional booster is being “very carefully monitored in real time, and recommendations, if needed, will be updated according to the data as it evolves.”

Fauci also said that he believes the timing of when the second booster would be administered is critical and that it “doesn’t make much sense” to administer the fourth dose now as omicron begins to fade.

Fauci suggested that it would be best to administer a second booster, if needed, in the fall or winter, when a new variant is more likely to emerge, CNN reports.

Both Pfizer-BioNTech and Moderna are currently developing omicron-specific vaccines, and both companies believe a fourth dose will eventually be necessary to keep protection levels high.

However, the CEO of BioNTech said Thursday that stalls in data evaluation have lead to a weeks-long delay in the development, as it still unclear whether or not these altered vaccines will be needed. It is also unclear whether or not a potential fourth dose approved by the FDA would be tailored to a new variant use the same formulation as previous doses. 

Israel was the first country to approve a second booster shot for certain citizens in December, while Sweden approved another booster for residents over the age of 80 on Monday.

Immunocompromised people in the U.S. have been eligible for a second booster shot since October, according to CDC guidelines.



Read original article here

FDA considering second COVID-19 booster in coming months

Food and Drug Administration (FDA) officials are “very carefully” considering second booster doses of the mRNA COVID-19 vaccines, according to The Wall Street Journal.

FDA spokesperson Alison Hunt confirmed to CNN that the FDA “is indeed continually looking at the emerging data on the pandemic and variants in the United States and overseas in order to evaluate the potential utility and composition of booster doses.”

Hunt also said that there is still much uncertainty, but the FDA is evaluating whether another booster dose will be needed when the country moves into the fall of 2022, which would coincide with the typical administration of annual flu shots, CNN noted.

“As more data become available about the safety and effectiveness of COVID-19 vaccines, including the use of a booster dose, we will continue to evaluate the rapidly changing science and keep the public informed,” Hunt wrote to CNN. “Any determination that additional booster doses are needed will be based on data available to the agency.”

If the FDA approves another booster dose, it would then face approval by the Centers for Disease Control and Prevention (CDC). 

Anthony FauciAnthony FauciFDA considering second COVID-19 booster in coming months GOP senator faces challenge on Trump credentials Britt in new ad tells ‘boys in Washington’ to ‘man up’ MORE, the head of the National Institute of Allergy and Infectious Diseases (NIAID), said the “potential future requirement” for an additional booster is being “very carefully monitored in real time, and recommendations, if needed, will be updated according to the data as it evolves.”

Fauci also said that he believes the timing of when the second booster would be administered is critical and that it “doesn’t make much sense” to administer the fourth dose now as omicron begins to fade.

Fauci suggested that it would be best to administer a second booster, if needed, in the fall or winter, when a new variant is more likely to emerge, CNN reports.

Both Pfizer-BioNTech and Moderna are currently developing omicron-specific vaccines, and both companies believe a fourth dose will eventually be necessary to keep protection levels high.

However, the CEO of BioNTech said Thursday that stalls in data evaluation have lead to a weeks-long delay in the development, as it still unclear whether or not these altered vaccines will be needed. It is also unclear whether or not a potential fourth dose approved by the FDA would be tailored to a new variant use the same formulation as previous doses. 

Israel was the first country to approve a second booster shot for certain citizens in December, while Sweden approved another booster for residents over the age of 80 on Monday.

Immunocompromised people in the U.S. have been eligible for a second booster shot since October, according to CDC guidelines.



Read original article here

COVID Omicron Updates: CDC releases new guidance for some Americans to get additional vaccine booster shot

NEW YORK (WABC) — The CDC has shortened the amount of time people who are moderately or severely immunocompromised need to wait before getting a fourth COVID vaccine booster dose.

They now recommend that the severely immunocompromised can get an additional Pfizer or Moderna shot three months after their third dose instead of five months.

The CDC also encourages people with weakened immune systems who originally got a Johnson & Johnson vaccine to take two additional doses, instead of just one.

RELATED: What are the symptoms of the COVID omicron variant?

Here are more of today’s COVID-19 headlines:

US death toll hits 900,000, sped by omicron
Propelled in part by the wildly contagious omicron variant, the U.S. death toll from COVID-19 hit 900,000 on Friday, less than two months after eclipsing 800,000. The two-year total, as compiled by Johns Hopkins University, is greater than the population of Indianapolis, San Francisco, or Charlotte, North Carolina. The milestone comes more than 13 months into a vaccination drive that has been beset by misinformation and political and legal strife, though the shots have proved safe and highly effective at preventing serious illness and death.

Scientists study why some never catch coronavirus
Scientists are trying to unlock the mystery of why some people seem never to catch COVID. While there is no clear-cut answer, one factor may lie in our DNA, giving people with certain genetic traits more pre-existing protection. Researchers in London have also found that people with higher levels of T-cells generated from other previous coronavirus infections like a common cold were less likely to get COVID. “If there are overlapping sequences that are shared between the common cold coronaviruses and the sarscov2, that T-cell can react very quickly to mount a defense against sarscov2,” said Dr. Akiko Iwasaki, professor of immunology, Yale University.

More vaccinations will lead to lifting mask rules: Hochul
Records show 80% of 12-to 17-year-olds in New York State have gotten their first dose of the COVID vaccine, and Gov. Kathy Hochul says more vaccinations will lead to the lifting of mask mandates in schools. “The more children we have vaccinated, the safer they will be in school,” she said, explaining vaccination rate will be a factor in decisions on mask rules. “And they wont need a mask anymore,” Hochul promised. “But we are just not there yet. It is all based on data.” Data shows 40% of 5-to 11-year-olds have gotten their first dose.

COVID falling in 49 of 50 states as deaths near 900,000
With omicron easing, new cases of COVID-19 in the U.S. are falling in 49 of the 50 states, even as the nation’s death toll closes in on another bleak round number: 900,000. The number of lives lost to the pandemic in the U.S. stood at about 899,000 as of Friday afternoon, with deaths running at an average of more than 2,400 a day, back up to where they were last winter, when the vaccine drive was still getting started. But new cases per day have tanked by almost a half-million nationwide since mid-January, the curve trending downward in every state but Maine.

CT crosses grim milestone
Connecticut reported an additional 175 COVID deaths since last week, bringing the state’s total across the 10,000 threshold to 10,083. The state’s positivity rate is currently 6.57%, with 869 current hospitalizations.

Palin resumes court battle with NY Times after COVID illness

Sarah Palin’s libel suit against The New York Times went to trial Thursday in a case over the former Alaska governor’s claims the newspaper damaged her reputation with an editorial linking her campaign rhetoric to a mass shooting. The trial is a rare example of a jury deciding the validity of a persistent refrain from Palin and other Republicans: That a biased news media is willing to bend the truth to make conservatives look bad. Palin, a one-time Republican vice presidential nominee, told journalists as she arrived at the courthouse that she was looking for “Justice for people who expect truth in the media.” Opening statements to the jury were initially scheduled for last week, but were postponed when Palin tested positive for COVID-19.
“We come to this case with our eyes wide open and keenly aware of the fact we’re fighting an uphill battle,” Palin attorney Shane Vogt said. “Give us a fair shot. We’re not here trying to win your votes for Governor Palin or any of her policies.”

Medicare opens up access to free at-home COVID-19 tests
The Biden administration says people with Medicare will be able to get up to eight free over-the-counter COVID-19 tests per month, starting in early spring. It’s seeking to fill a frustrating gap in coverage for coronavirus tests. Last month, the administration directed private insurers to cover rapid COVID-19 tests for people on their plans. But until now officials were trying to figure out what to do about Medicare, which covers older people particularly vulnerable to severe illness from COVID-19. Laws and regulations that govern the program stood in the way. Free tests will be available through participating pharmacies and other locations. AARP has praised Medicare’s decision.

Russia mulls loosening restrictions amid record virus surge
The Russian president says his government is considering loosening some coronavirus restrictions, even as the country is facing a record-breaking surge of infections because of the highly contagious omicron variant. Vladimir Putin on Thursday insisted that authorities are not planning any lockdowns or other additional restrictions because of the surge. Moreover, the government is considering lifting restrictions for those who come into contact with COVID-19 patients, “to give people the opportunity to continue working in peace.” Existing regulations mandate that people who come in contact with someone with COVID-19 must self-isolate for seven days. On Thursday, the country’s state coronavirus task force reported 155,768 new infections, a daily tally 10 times higher than a month ago.

How many times can I reuse my N95 mask?
How many times can I reuse my N95 mask? It depends, but you should be able to use N95s and KN95s a few times. The U.S. Centers of Disease Control and Prevention says health care workers can wear an N95 mask up to five times. But experts say how often the average person can safely wear one will vary depending on how it’s used. Using the same mask to run to the grocery store, for example, is very different than wearing it all day at work.
When am I contagious if infected with omicron?

When am I contagious if infected with omicron? It’s not yet clear, but some early data suggests people might become contagious sooner than with earlier variants – possibly within a day after infection. The U.S. Centers for Disease Control and Prevention says people with the coronavirus are most infectious in the few days before and after symptoms develop. But that window of time might happen earlier with omicron, according to some outside experts. That’s because omicron appears to cause symptoms faster than previous variants – about three days after infection, on average, according to preliminary studies. Based on previous data, that means people with omicron could start becoming contagious as soon as a day after infection.

MORE CORONAVIRUS COVID-19 COVERAGE

Omicron variant symptoms: what to know even if you are vaccinated
New York City COVID-19 Vaccine Tracker
New Jersey COVID-19 Vaccine Tracker
Centers for Disease Control and Prevention on coronavirus

Submit a News Tip or Question

Copyright © 2022 WABC-TV. All Rights Reserved.



Read original article here

Fauci: COVID Vaccines For Kids Under 5 Could Be Approved By Next Month

In news sure to cheer the exhausted parents of toddlers everywhere, the Food and Drug Administration could approve a COVID-19 vaccine for kids under the age of 5 as soon as next month.

White House chief medical adviser Dr. Anthony Fauci said Wednesday the FDA is awaiting data from a trial determining the adequate dosage for the Pfizer-BioNTech vaccine. If the data looks favorable, the FDA could sign off in short order.

“My hope is that it’s going to be within the next month or so and not much later than that,” Fauci told Blue Star Families, a nonprofit group that helps military families.

“But I can’t guarantee that because I can’t out-guess the FDA,” he cautioned. “I’m going to have to leave that to them.”

Pfizer said last month it expects to submit the data in the first half of 2022.

Early results suggest children age 6 to 24 months would receive a high degree of protection from a two-dose regimen, while children between the age of 2 and 5 years would receive three.

Hannah Beltram, 6, high-fives Dr. Eugenio Fernandez after she received the Pfizer COVID-19 vaccine for children in Providence, Rhode Island, on Nov. 5, 2021.

The likely dose per shot for younger children, 3 micrograms, is much smaller than the 10-microgram pediatric formulation that’s been approved for children age 5 to 12. Adults, meanwhile, get a per-shot dose of 30 micrograms.

Children under 5 are the only group so far who aren’t eligible for a vaccine, leaving them especially vulnerable to COVID-19 amid a nationwide surge in the omicron variant, which is infecting children in record numbers.

While age seems to be a significant risk factor in the severity of the disease, children nevertheless remain at risk, Fauci said.

“It is true that a child that gets infected is much less likely to get a severe manifestation of COVID,” he told Blue Star Families. “However, the risk is not zero and when you look at children’s hospitals throughout the country, we have plenty of children who are severely ill with COVID-19, requiring hospitalization, some even dying.

“So even though the risk is less than an adult, you have to balance.”

fbq('init', '1621685564716533'); fbq('track', "PageView");

var _fbPartnerID = null; if (_fbPartnerID !== null) { fbq('init', _fbPartnerID + ''); fbq('track', "PageView"); }

(function () { 'use strict'; document.addEventListener('DOMContentLoaded', function () { document.body.addEventListener('click', function(event) { fbq('track', "Click"); }); }); })();

Read original article here